RT Journal Article
T1 Efficacy of alemtuzumab in relapsing-remitting MS patients who received additional courses after the initial two courses: Pooled analysis of the CARE-MS, extension, and TOPAZ studies.
A1 Comi, Giancarlo
A1 Alroughani, Raed
A1 Boster, Aaron L
A1 Bass, Ann D
A1 Berkovich, Regina
A1 Fernández, Óscar
A1 Kim, Ho Jin
A1 Limmroth, Volker
A1 Lycke, Jan
A1 Macdonell, Richard Al
A1 Sharrack, Basil
A1 Singer, Barry A
A1 Vermersch, Patrick
A1 Wiendl, Heinz
A1 Ziemssen, Tjalf
A1 Jacobs, Alan
A1 Daizadeh, Nadia
A1 Rodriguez, Claudio E
A1 Traboulsee, Anthony
A1 CARE-MS I, CARE-MS II, CAMMS03409, and TOPAZ Investigators
K1 Alemtuzumab
K1 efficacy
K1 multiple sclerosis
K1 relapse
K1 retreatment
K1 safety
AB Alemtuzumab is given as two annual courses. Patients with continued disease activity may receive as-needed additional courses. To evaluate efficacy and safety of additional alemtuzumab courses in the CARE-MS (Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis) studies and their extensions. Subgroups were based on the number of additional alemtuzumab courses received. Exclusion criteria: other disease-modifying therapy (DMT);  In the additional-courses groups, Courses 3 and 4 reduced annualized relapse rate (12 months before: 0.73 and 0.74, respectively; 12 months after: 0.07 and 0.08). For 36 months after Courses 3 and 4, 89% and 92% of patients were free of 6-month confirmed disability worsening, respectively, with 20% and 26% achieving 6-month confirmed disability improvement. Freedom from magnetic resonance imaging (MRI) disease activity increased after Courses 3 and 4 (12 months before: 43% and 53%, respectively; 12 months after: 73% and 74%). Safety was similar across groups; serious events occurred irrespective of the number of courses. Additional alemtuzumab courses significantly improved outcomes, without increased safety risks, in CARE-MS patients with continued disease activity after Course 2. How this compares to outcomes if treatment is switched to another DMT instead remains unknown.
YR 2019
FD 2019-11-25
LK http://hdl.handle.net/10668/14739
UL http://hdl.handle.net/10668/14739
LA en
DS RISalud
RD Apr 8, 2025